TL;DR: The Centers for Medicare & Medicaid Services modified NCD 137, its laetrile coverage policy, effective March 7, 2026. Medicare does not cover laetrile or any related substance under any clinical circumstance — and this policy update makes that position even clearer for billing teams.
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Laetrile and Related Substances — NCD 137 |
| Policy Code | NCD 137 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Low (zero covered indications — but high risk if claims are submitted) |
| Specialties Affected | Oncology, integrative/alternative medicine, hospital billing, outpatient infusion |
| Key Action | Flag any claims involving laetrile, amygdalin, or related substances before submission — all are non-covered under Medicare |
What Is NCD 137 and Why Did CMS Update It in 2026?
NCD 137 is the National Coverage Determination governing Medicare coverage of laetrile and related substances — including amygdalin, Sarcarcinase, vitamin B-17, and nitriloside. The Centers for Medicare & Medicaid Services classifies this policy under the Drugs and Biologicals benefit category, specifically as a service incident to a physician's professional service.
The modification effective March 7, 2026 doesn't change the clinical outcome — laetrile remains non-covered — but it refreshes the policy's standing in CMS's NCD framework. That matters for your billing team because it resets the documentation trail and puts this policy back on regulators' radar.
If you bill oncology or infusion services and see laetrile-adjacent claims come through, this is your signal to tighten up your front-end edits now.
CMS Laetrile Coverage Criteria and Medical Necessity Requirements 2026
The CMS laetrile coverage policy is unambiguous: there are no covered indications. Zero. The FDA determined that laetrile — and every substance described by the terms amygdalin, Sarcarcinase, vitamin B-17, and nitriloside — is not generally recognized as safe or effective for any therapeutic use.
That FDA determination is load-bearing here. CMS ties non-coverage directly to §1862(a)(1) of the Social Security Act. That's the "reasonable and necessary" standard. Because the FDA says laetrile fails the safety and effectiveness test, CMS concludes it cannot meet the reasonable and necessary threshold — and that means no reimbursement, period.
Medical necessity is not a question of clinical judgment in this case. No amount of physician documentation, patient consent, or alternative literature changes the coverage outcome. The policy forecloses the medical necessity argument entirely.
There is no prior authorization pathway here, because prior authorization implies a route to approval. NCD 137 doesn't offer one. The service is excluded at the benefit category level.
CMS Laetrile Exclusions and Non-Covered Indications
Every use of laetrile — and its related substances — is excluded from Medicare coverage. The policy draws no distinction between patient populations, cancer types, or clinical settings. That scope matters for your billing team.
The policy specifically calls out two scenarios that billing staff sometimes assume might be gray areas. They are not.
Inpatient hospital stays: A hospital admission solely for laetrile administration is not covered. This isn't just about the drug itself — the entire stay is excluded when laetrile is the reason for admission.
Incidental use during a covered stay: If a patient is admitted for a legitimate, covered reason and receives laetrile during that stay, Medicare still will not pay for the laetrile or any services connected to its administration. The covered portions of the stay aren't at risk, but anything tied to laetrile administration is.
The phrase "any services furnished in connection with its administration" is the one to watch. That language is broad. It can sweep in nursing time, IV supplies, pharmacy charges, and monitoring services if they're tied to laetrile delivery. Don't assume ancillary services are safe just because you're not billing the drug itself.
This is the real issue for billing teams: it's not just about the drug code. It's about the web of associated charges that can follow a laetrile administration note into your claim.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Laetrile for cancer treatment or control | Not Covered | None listed | Excluded under §1862(a)(1) — not reasonable and necessary |
| Amygdalin for any therapeutic use | Not Covered | None listed | Treated as equivalent to laetrile under this NCD |
| Sarcarcinase for any therapeutic use | Not Covered | None listed | Treated as equivalent to laetrile under this NCD |
| Vitamin B-17 / nitriloside for any therapeutic use | Not Covered | None listed | Treated as equivalent to laetrile under this NCD |
| Hospital admission solely for laetrile administration | Not Covered | None listed | Entire stay is excluded, not just the drug |
| Laetrile administered during an otherwise covered inpatient stay | Not Covered | None listed | Covered stay is not affected, but laetrile and related services are excluded |
| Any services furnished in connection with laetrile administration | Not Covered | None listed | Ancillary charges tied to administration are also excluded |
CMS Laetrile Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 is the line in the sand. Here's what your team does before and after it.
| # | Action Item |
|---|---|
| 1 | Audit your charge master and encounter forms for any laetrile-related entries. Search for laetrile, amygdalin, Sarcarcinase, vitamin B-17, and nitriloside. If any of these appear in your charge capture system, flag them for immediate review. A charge that can't be billed shouldn't sit in your master file unchecked. |
| 2 | Add front-end claim edits to catch laetrile-related charges before submission. Because the policy lists no specific CPT or HCPCS codes, you need to build edits around drug names and NDC numbers rather than procedure codes. Work with your billing system vendor if needed — this is a drug description flag, not a code flag. |
| 3 | Train your coding and clinical documentation staff on the "in connection with" language. Any ancillary service documented as supporting laetrile administration is non-covered. Make sure coders know to identify and separate those charges rather than bundle them into covered services. |
| 4 | Review any inpatient claims where laetrile appears in clinical notes, even if not billed. If a patient received laetrile during a covered stay and the documentation reflects that, your claim is exposed. The drug charge may have been left off the bill, but auditors can and do follow clinical notes to challenge associated charges. |
| 5 | Do not attempt to bill laetrile services with an unlisted drug code and hope for the best. Some teams try this with non-covered drugs. It doesn't work here. NCD 137 is a national coverage determination — it applies to every Medicare Administrative Contractor across every region. There's no local coverage determination workaround and no MAC-level exception. |
| 6 | If a patient specifically requests laetrile and you're counseling them on options, document that counseling as a separate, billable E/M service. The physician's time spent advising a patient about treatment options — including why laetrile isn't a covered or clinically supported option — is a legitimate clinical service. Don't let a non-covered drug request become a non-billable encounter. |
| 7 | If your practice or facility has any integrative or alternative medicine services, loop in your compliance officer now. The "in connection with" language in NCD 137 is broad enough that a compliance officer should review how your service lines document and bill supporting services. Do this before March 7, 2026. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Laetrile Under NCD 137
A Note on Laetrile Billing Codes
The policy does not list specific CPT, HCPCS, or ICD-10 codes. This is consistent with the nature of the coverage policy — because no laetrile billing is permitted, there are no approved billing codes to reference. CMS has not assigned a payable code pathway for this service.
This absence of codes is itself a billing signal. If your team encounters a charge for laetrile, amygdalin, Sarcarcinase, vitamin B-17, or nitriloside and someone asks "what code do we use?" — the answer is: you don't. The service is non-covered. Submitting it under an unlisted or miscellaneous code will result in a claim denial, and in the worst case, it creates a false claims exposure.
The billing guidelines here aren't about code selection. They're about claim prevention.
What to Expect If a Claim Is Submitted
A claim denial is the best-case outcome if a laetrile-related charge reaches a Medicare payer. The denial reason will reference the reasonable and necessary standard under §1862(a)(1). There's no appeal pathway that overrides an NCD — NCDs are binding on all MACs and cannot be overridden at the local level.
If you're billing laetrile charges today and wondering whether a particular code might slip through, stop. The NCD framework doesn't leave gaps here. The policy is explicit that payment may not be made for the drug or any services connected to its administration.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.